Yifan Wang

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda et al. · Journal of Hepatology · 2021 · 1.5K citations · Full text

Hepatology, Atezolizumab Plus Bevacizumab, Unresectable Hepatocellular Carcinoma +9

Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation

Zhaogang Yang, Junfeng Shi, Jing Xie et al. · Nature Biomedical Engineering · 2019 · 689 citations · Full text

Cell-based Drug Delivery, Nanomedicine, Cellular Nanoporation +6

Disrupting the Interaction of BRD4 with Diacetylated Twist Suppresses Tumorigenesis in Basal-like Breast Cancer

Jian Shi, Yifan Wang, Lei Zeng et al. · Cancer Cell · 2014 · 486 citations · Full text

Breast Oncology, Medicine, Breast Cancer +7

G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer

Chenfang Dong, Yadi Wu, Jun Yao et al. · Journal of Clinical Investigation · 2012 · 442 citations · Full text

Epigenetic Change, Dna Methylation, Human Breast Cancer +22

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

Leisha A. Emens, Francisco J. Esteva, Mark Beresford et al. · The Lancet Oncology · 2020 · 363 citations

Breast Oncology, Oncology, Pharmacology +7